Little House Capital LLC Acquires 5,593 Shares of Pfizer Inc. (NYSE:PFE)

Little House Capital LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,196 shares of the biopharmaceutical company’s stock after buying an additional 5,593 shares during the period. Little House Capital LLC’s holdings in Pfizer were worth $1,163,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Olistico Wealth LLC bought a new position in Pfizer in the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer in the 2nd quarter worth about $29,000. Quarry LP bought a new position in Pfizer in the 2nd quarter worth about $31,000. Trivant Custom Portfolio Group LLC boosted its stake in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new position in Pfizer in the 2nd quarter worth about $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock traded down $0.29 during midday trading on Monday, hitting $28.93. The stock had a trading volume of 13,213,070 shares, compared to its average volume of 36,989,422. The firm’s fifty day moving average is $29.07 and its two-hundred day moving average is $28.45. The company has a market capitalization of $163.93 billion, a PE ratio of -483.67, a P/E/G ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.81%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Thursday, October 3rd. UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.91.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.